A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

This study has been completed.
Sponsor:
Collaborators:
MedImmune Ltd
AstraZeneca
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01093040
First received: March 19, 2010
Last updated: August 29, 2012
Last verified: August 2012

March 19, 2010
August 29, 2012
April 2010
May 2010   (final data collection date for primary outcome measure)
Safety [ Time Frame: Study Day 71 ] [ Designated as safety issue: Yes ]
The safety and tolerability of a single dose SC injection of CAT-354 in healthy male and/or female Japanese subjects will be assessed through the incidence of adverse events (AEs), and the assessment of vital signs, physical examinations, laboratory parameters, and electrocardiograms.
Same as current
Complete list of historical versions of study NCT01093040 on ClinicalTrials.gov Archive Site
Immunogenicity [ Time Frame: Study Day 71 ] [ Designated as safety issue: No ]
The PK variables and IM variables of CAT-354 in healthy Japanese subjects will be evaluated. The incidence rate of positive serum antibodies to CAT-354 will be reported by treatment group.
Same as current
Not Provided
Not Provided
 
A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
A Phase I, Single-Center, Single-blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CAT-354 Following Subcutaneous Administration in Healthy Male and Female Japanese Subjects

To assess the safety of the administration of the drug (CAT-354) in healthy Japanese subjects.

The study design allows a gradual escalation of dose with safety monitoring to ensure the safety of the subjects.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Healthy
  • Drug: CAT-354
    150 mg CAT-354 or placebo given SC on Day 1
  • Drug: CAT-354
    300 mg CAT-354 or placebo given SC on Day 1
  • Drug: CAT 354
    600 mg CAT-354 or placebo given SC on Day 1
  • Experimental: Cohort 1
    CAT-354 will be administered by SC injection
    Intervention: Drug: CAT-354
  • Experimental: Cohort 2
    CAT-354 will be administered by SC injection
    Intervention: Drug: CAT-354
  • Experimental: Cohort 3
    CAT-354 will be administered by SC injection
    Intervention: Drug: CAT 354
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
October 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects aged 20 through 55 years at the time of screening
  • Signed and dated written informed consent is obtained prior to any study related procedure taking place
  • No significant abnormality on clinical examination or medical history (excluding atopic skin signs, symptoms and history)
  • A normal 12-lead electrocardiogram (ECG) (no clinically significant abnormalities)
  • Clinical chemistry, hematology and urinalysis results within the laboratory reference ranges or deemed not clinically significant by the Investigator
  • A negative screen for drugs of abuse and alcohol
  • The following reproductive criteria apply:
  • Females(of child bearing potential) must have a negative pregnancy test prior to the dose of investigational product and, unless surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), has a sterile male partner, or at least 2 years postmenopausal, or practices abstinence; must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted hormonal contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap with spermicide, or use of a condom with spermicide by the sexual partner) for 21 days prior to randomization, and must agree to continue using such precautions until 3 months after dosing with the investigational product; cessation of birth control after this point should be discussed with a responsible physician. A negative pregnancy test is required both at screening and prior to dosing.
  • Males, unless surgically sterile, must use two effective methods of birth control with a female partner and must agree to continue using such contraceptive precautions from 21 days prior to randomization until 3 months after dosing with the investigational product.
  • Japanese subjects. To be considered as 'Japanese', both of the subject's parents, and both sets of grandparents, must be Japanese. The subject must have been born in Japan, have a valid Japanese passport, and must not have lived outside Japan for more than 5 years.
  • Body mass index (BMI) between 18 and 27 kg/m 2 , inclusive
  • Able to comply with the requirements of the protocol

Exclusion Criteria:

  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
  • Previously received monoclonal antibody, or a similar related protein, that might sensitize subjects to CAT-354 or to any component of the investigational product formulation
  • History of an active infection within 4 weeks prior to screening, or evidence of clinically significant active infection, including ongoing chronic infection
  • Any acute illness in the 14 days before Day 1 (Visit 2)
  • Use of any medication (prescription or OTC) excluding hormonal contraception within 14 days (or 5-half lives, whichever is longer) of Day 1 dosing
  • Involvement in another study of investigational medicinal product; within 2 months of the start of this study (Day 1) for small molecules, within 3 months of the start of this study for antibodies, or 5 half lives of the previously administered investigational product, whichever is the longer
  • Any blood donation or significant loss of blood within 56 days of study initiation or plasma donation within 7 days of study initiation
  • Subjects with immunodeficiency disorders
  • Subjects who have a positive test for, or have been treated for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
  • Any active concomitant disease including psychological disorders
  • Subject is a participating Investigator, sub-Investigator, study coordinator, or employee of a participating Investigator, or is a first-degree relative of the aforementioned.
  • Any factor which, in the opinion of the Investigator, would be associated with poor adherence to the protocol
  • Female subjects: lactation
Both
20 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01093040
MI-CP224
No
MedImmune LLC
MedImmune LLC
  • MedImmune Ltd
  • AstraZeneca
Study Director: Katsuro Yagawa, M.D. Astra Zeneca K.K.
MedImmune LLC
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP